Aristolochic acids exposure was not the main cause of liver tumorigenesis in adulthood

Acta Pharm Sin B. 2022 May;12(5):2252-2267. doi: 10.1016/j.apsb.2021.11.011. Epub 2021 Nov 16.

Abstract

Aristolochic acids (AAs) have long been considered as a potent carcinogen due to its nephrotoxicity. Aristolochic acid I (AAI) reacts with DNA to form covalent aristolactam (AL)-DNA adducts, leading to subsequent A to T transversion mutation, commonly referred as AA mutational signature. Previous research inferred that AAs were widely implicated in liver cancer throughout Asia. In this study, we explored whether AAs exposure was the main cause of liver cancer in the context of HBV infection in mainland China. Totally 1256 liver cancer samples were randomly retrieved from 3 medical centers and a refined bioanalytical method was used to detect AAI-DNA adducts. 5.10% of these samples could be identified as AAI positive exposure. Whole genome sequencing suggested 8.41% of 107 liver cancer patients exhibited the dominant AA mutational signature, indicating a relatively low overall AAI exposure rate. In animal models, long-term administration of AAI barely increased liver tumorigenesis in adult mice, opposite from its tumor-inducing role when subjected to infant mice. Furthermore, AAI induced dose-dependent accumulation of AA-DNA adduct in target organs in adult mice, with the most detected in kidney instead of liver. Taken together, our data indicate that AA exposure was not the major threat of liver cancer in adulthood.

Keywords: AAI, Aristolochic acid I; AAs, aristolochic acids; AA–DNA adduct; AFP, alpha fetoprotein; AL, aristolactam; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Aristolochic acids (AAs); CHERRY, Chinese Electronic Health Records Research; COSMIC, Catalogue of Somatic Mutations in Cancer; CRE, creatinine; DEN, N-nitrosodiethylamine; EHBH, Eastern Hepatobiliary Surgery Hospital; FFPE, formalin-fixed paraffin-embedded; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC); Liver tumorigenesis; MVI, microvessel invasion; Mutational signature; Risk factors; SNV, somatic single nucleotide variant; TCGA, The Cancer Genome Atlas; Tumor prevention; WGS, whole genome sequencing; WT, wild type; dA-ALI, 7-deoxyadenosin-N6-yl aristolactam I.